PharmaResearch (214450)

KOSDAQ · 442,000 KRW · As of Aug 26, 2026 close

1Y Close · As of Aug 26, 2026

300,000400,000500,000600,000 H 680,000L 259,000 25.0826.0526.08
Mkt Cap
4.6T
Rev (2025)
536.3B
Op Inc (2025)
214.4B
Net Inc (2025)
168.3B
PBR
6.34
52W
259K~680K

PharmaResearch operates in the Pharmaceuticals sector.

Legal name: PharmaResearch Co., Ltd.

In fiscal year 2025, PharmaResearch (214450) reported revenue of 536.3 billion KRW, up 53.2% from 350.1 billion KRW a year earlier.

Operating profit was 214.4 billion KRW and net income was 168.3 billion KRW in the same year.

As of the Aug 26, 2026 close, the market capitalization was 4.59 trillion KRW, with a P/B of 6.34.

These figures can be verified in the DART filing (receipt no. 20260319001417).

Financials

YearRevOp IncNet Inc
2025536.3B214.4B168.3B
2024350.1B126.1B88.9B
2023261.0B92.3B77.3B

Full financials →

Checks

1 applicable out of 8 items

Check details →

Recent Filings

Semi-Annual Report (2026.06)

Consolidated Operating (Preliminary) Earnings (Fair Disclosure)

Corporate Briefing (IR)

All filings →

Checks

1 of 8 checked items currently applicable.

Market Cap & Price: Market cap is above the delisting threshold.

Administrative Designation: No administrative designation criteria met.

Audit Opinion: Audit opinion: Unqualified (clean).

Convertible Bonds: Convertible bonds outstanding with 0.03% potential dilution.

Capital Increase: No capital-increase filings in the last 180 days.

Treasury Stock: No treasury stock filings.

Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.

Major Shareholder Change: No major shareholder changes in the last 180 days.

Market Action: No market actions recorded in the last 180 days.

These checks are mechanical tests of disclosed figures and do not constitute investment advice or recommendations.

Recent Filings

DateFiling
2026-08-14Semi-Annual Report (2026.06)
2026-08-07Consolidated Operating (Preliminary) Earnings (Fair Disclosure)
2026-08-06Corporate Briefing (IR)